Exelixis claims a next-generation colorectal win
Zanzalintinib prevails in all comers, but full data will show if the win was driven by a subgroup.
Zanzalintinib prevails in all comers, but full data will show if the win was driven by a subgroup.
The move follows promising but early data presented at ASCO.
Lilly, Merck & Co and Verastem could take on Amgen, Bristol and Revolution.
April saw a checkpoint inhibitor bonanza for Bristol and Akeso.
Merck & Co gives up on Agenus, while Sanofi hands BND-22 back to Biond.
AstraZeneca bags three of the month’s four oncology approvals.
On a wing and a prayer Leap heads for phase 3.